KC
ABUS icon

Kepos Capital’s Arbutus Biopharma ABUS Stock Holding History

Kepos Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-155,691
Closed -$316K – 223
2023
Q3 		$316K Sell
155,691
-44,309
-22% -$92.9K 0.06% 94
2023
Q2 		$460K Buy
+200,000
New +$521K 0.08% 101
2022
Q4 		$466K Hold
200,000
– – 0.07% 113
2022
Q3 		$382K Hold
200,000
– – 0.05% 149
2022
Q2 		$542K Hold
200,000
– – 0.05% 149
2022
Q1 		$596K Hold
200,000
– – 0.04% 208
2021
Q4 		$778K Buy
+200,000
New +$777K 0.06% 220

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kepos Capital's ABUS Position: Q4 2023 in Review

Kepos Capital sold out of Arbutus Biopharma (ABUS) in Q4 2023, closing a stake of 155,691 shares — an estimated $316K sold.

Kepos Capital first reported a position in ABUS in Q4 2021 and held it in 7 quarters. The position peaked at $778K in Q4 2021. 112 funds tracked by Wall St. Rank hold ABUS as of Q4 2023.

  • Kepos Capital reported no remaining Arbutus Biopharma position as of Q4 2023 after selling out during the quarter.
  • Kepos Capital sold 155,691 Arbutus Biopharma shares in Q4 2023, an estimated $316K.
  • Kepos Capital first reported a position in Arbutus Biopharma in Q4 2021 and held it in 7 quarters.
  • Kepos Capital's Arbutus Biopharma position peaked at $778K in Q4 2021.
  • 112 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2023.

Based on Kepos Capital's 13F filing for Q4 2023, filed 12 Feb 2024.